CFO
LGND icon

Callan Family Office’s Ligand Pharmaceuticals LGND Stock Holding History

Callan Family Office’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change % 		Capital Flow Portfolio Weight Portfolio Position
2025
Q2 		$326K Buy
2,864
+426
+17% +$48.4K 0.01% 742
2025
Q1 		$256K Hold
2,438
– – 0.02% 464
2024
Q4 		$261K Buy
+2,438
New +$261K 0.02% 529